Claims
- 1. A method for treating a vascular condition, said method comprising:
administering to a human patient in need thereof a therapeutically effective amount of a combination of at least two agents selected from the group consisting of an anti-pressor agent, an endothelin antagonist, and a sex hormone, wherein said vascular condition is treated.
- 2. The method of claim 1, wherein said vascular condition is selected from the group consisting of a sexual dysfunction, atherosclerosis, renal failure, hypertension, congestive heart failure, diabetic nephropathy, and diabetic neuropathy.
- 3. The method of claim 1, wherein said anti-pressor agent is selected from the group consisting of prostaglandin-E1, an ACE inhibitor, an angiotensin-II receptor antagonist, an α1-adrenergic receptor antagonist, a β-adrenergic receptor antagonist, a calcium channel blocker, an activator of guanylyl cyclase, an activator of adenyl cyclase, a phosphodiesterase inhibitor, and hydralazine.
- 4. The method of claim 3, wherein said ACE inhibitor is selected from the group consisting of alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, fosinopril, imidapril, lacidipine, libenzapril, lisinopril, moexipril, moveltipril, pentopril, perindopril, quinapril, ramipril, spirapril, temocapril, and trandolapril.
- 5. The method of claim 3, wherein said ACE inhibitor is enalapril.
- 6. The method of claim 3, wherein said angiotensin-II receptor antagonist is selected from the group consisting of eprosartan, irbesartan, losartan, and valsartan.
- 7. The method of claim 3, wherein said angiotensin-II receptor antagonist is losartan.
- 8. The method of claim 3, wherein said α1-adrenergic receptor antagonist is selected from the group consisting of alfuzosin, apraclonidine, bunazosin, carvedilol, clonidine, dapiprazole, doxazosin, indoramin, labetolol, midrodrine, naphazoline, phenoxybenzamine, phentolamine, prazosin, tamsulosin, terazosin, trimazosin, and urapidil.
- 9. The method of claim 3, wherein said calcium channel blocker is selected from the group consisting of bepridil, diltiazem, mibrefadil, nicardipine, nifedipine, nimopidine, and verapamil.
- 10. The method of claim 3, wherein said activator of guanylyl cyclase or adenyl cyclase is selected from the group consisting of YC-1 and forskolin.
- 11. The method of claim 3, wherein said phosphodiesterase inhibitor is selected from the group consisting of amrinone and sildenafil.
- 12. The method of claim 1, wherein said endothelin antagonist is selected from the group consisting of a peptidal endothelin antagonist, a non-peptidal endothelin antagonist, and an inhibitor of endothelin converting enzyme.
- 13. The method of claim 12, wherein said peptidal endothelin antagonist is an ETA/ETB receptor antagonist.
- 14. The method of claim 13, wherein said ETA/ETB receptor antagonist is PD145065.
- 15. The method of claim 12, wherein said non-peptidal endothelin antagonist is bosentan.
- 16. The method of claim 12, wherein said inhibitor of endothelin converting enzyme is phosphoramidon.
- 17. The method of claim 1, wherein said sex hormone is a testosterone-like compound.
- 18. The method of claim 1, wherein said sex hormone is an estrogen-like compound.
- 19. The method of claim 17, wherein said at least two agents are an ACE inhibitor and testosterone.
- 20. The method of claim 1, wherein said endothelin antagonist eliminates or reduces anti-pressor tolerance.
- 21. The method of claim 1, wherein said at least two agents are co-administered for at least two treatment cycles separated by a drug-free period.
- 22. The method of claim 21, wherein said at least two treatment cycles have different durations.
- 23. The method of claim 21, wherein said at least two agents are co-administered for at least two treatment cycles of at least 7 days, with each said treatment cycle being separated by a drug-free period of at least 7 days.
- 24. The method of claim 21, wherein said at least two agents are co-administered for at least two treatment cycles of about 14 days, with each said treatment cycle being separated by a drug-free period of about 14 days.
- 25. The method of claim 21, wherein said at least two agents are co-administered for at least three treatment cycles separated by a drug-free period having different durations.
- 26. A method for treating a vascular condition associated with a male or female sexual dysfunction, said method comprising:
administering to a human patient in need thereof a therapeutically effective amount of a combination of at least two agents selected from the group consisting of an anti-pressor agent, an endothelin antagonist, and a sex hormone, wherein said vascular condition associated with a male or female sexual dysfunction is treated.
- 27. The method of claim 26, wherein said male sexual dysfunction is selected from the group consisting of erectile dysfunction, priapism, and premature ejaculation.
- 28. The method of claim 26, wherein said female sexual dysfunction is selected from the group consisting of vaginal lubrication, vaginal engorgement, pain during intercourse, dyspareunia, an urogenital infection, post-menopause, diabetes, vascular disease, an estrogen depletion condition, idiosyncratic vaginal dryness, vaginismus, vulvodynia, interstitial cystitis, nonspecific urethritis, a sexual arousal disorder, hypoactive desire disorder and a sexual orgasmic disorder.
- 29. The method of claim 26, wherein said anti-pressor agent is selected from the group consisting of prostaglandin-E1, an ACE inhibitor, an angiotensin-II receptor antagonist, an α1-adrenergic receptor antagonist, a β-adrenergic receptor antagonist, a calcium channel blocker, an activator of guanylyl cyclase, an activator of adenyl cyclase, a phosphodiesterase inhibitor, and hydralazine.
- 30. The method of claim 29, wherein said ACE inhibitor is selected from the group consisting of alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, fosinopril, imidapril, lacidipine, libenzapril, lisinopril, moexipril, moveltipril, pentopril, perindopril, quinapril, ramipril, spirapril, temocapril, and trandolapril.
- 31. The method of claim 29, wherein said ACE inhibitor is enalapril.
- 32. The method of claim 29, wherein said angiotensin-II receptor antagonist is selected from the group consisting of eprosartan, irbesartan, losartan, and valsartan.
- 33. The method of claim 29, wherein said angiotensin-II receptor antagonist is losartan.
- 34. The method of claim 29, wherein said α1-adrenergic receptor antagonist is selected from the group consisting of alfuzosin, apraclonidine, bunazosin, carvedilol, clonidine, dapiprazole, doxazosin, indoramin, labetolol, midrodrine, naphazoline, phenoxybenzamine, phentolamine, prazosin, tamsulosin, terazosin, trimazosin, and urapidil.
- 35. The method of claim 29, wherein said calcium channel blocker is selected from the group consisting of bepridil, diltiazem, mibrefadil, nicardipine, nifedipine, nimopidine, and verapamil.
- 36. The method of claim 29, wherein said activator of guanylyl cyclase or adenyl cyclase is selected from the group consisting of YC-1 and forskolin.
- 37. The method of claim 29, wherein said phosphodiesterase inhibitor is selected from the group consisting of amrinone and sildenafil.
- 38. The method of claim 26, wherein said endothelin antagonist is selected from the group consisting of a peptidal endothelin antagonist, a non-peptidal endothelin antagonist, and an inhibitor of endothelin converting enzyme.
- 39. The method of claim 38, wherein said peptidal endothelin antagonist is an ETA/ETB receptor antagonist.
- 40. The method of claim 39, wherein said ETA/ETB receptor antagonist is PD145065.
- 41. The method of claim 38, wherein said non-peptidal endothelin antagonist is bosentan.
- 42. The method of claim 38, wherein said inhibitor of endothelin converting enzyme is phosphoramidon.
- 43. The method of claim 26, wherein said sex hormone is a testosterone-like compound.
- 44. The method of claim 26, wherein said sex hormone is an estrogen-like compound.
- 45. The method of claim 43, wherein said at least two agents are an ACE inhibitor and testosterone.
- 46. The method of claim 26, wherein said endothelin antagonist eliminates or reduces anti-pressor tolerance.
- 47. The method of claim 26, wherein said at least two agents are co-administered for at least two treatment cycles separated by a drug-free period.
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. application Ser. No. 10/192,281, filed Jul. 9, 2002, which is a continuation of U.S. application Ser. No. 09/902,787, filed Jul. 12, 2001, now U.S. Pat. No. 6,458,797, which application is a continuation of U.S. application Ser. No. 09/382,749, filed Aug. 25, 1999, now U.S. Pat. No. 6,284,763, and which application claims priority to U.S. Provisional Application No. 60/098,178, filed Aug. 26, 1998. The present application claims priority to U.S. Provisional Application No. 60/377,917, filed May 2, 2002. All the foregoing applications are incorporated herein by reference in their entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60098178 |
Aug 1998 |
US |
|
60377917 |
May 2002 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09902787 |
Jul 2001 |
US |
Child |
10192281 |
Jul 2002 |
US |
Parent |
09382749 |
Aug 1999 |
US |
Child |
09902787 |
Jul 2001 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10192281 |
Jul 2002 |
US |
Child |
10429197 |
May 2003 |
US |